ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1617
CHEMBL1617
Compound Name RIFAXIMIN
ChEMBL Synonyms TARGAXAN | XIFAXANTA | RIFAXIDIN | NORMIX | RIFAXIMIN | Rifacol | XIFAXAN
Max Phase 4 (Approved)
Trade Names XIFAXANTA | TARGAXAN | NORMIX | Rifacol | XIFAXAN
Molecular Formula C43H51N3O11

Additional synonyms for CHEMBL1617 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)\C(=C/C=C/[C ...
Download SMILES
Standard InChI InChI=1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37( ...
Download InChI
Standard InChI Key NZCRJKRKKOLAOJ-XRCRFVBUSA-N

Sources

  • British National Formulary
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL1617

Molecule Features

CHEMBL1617 compound icon
Drug Type:Natural Product-derived Rule of Five:N First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Bacterial DNA-directed RNA polymerase inhibitor Bacterial DNA-directed RNA polymerase DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Crohn DiseaseD003424EFO:0000384Crohn's disease3ClinicalTrials
Hepatitis CD006526EFO:0003047hepatitis C infection2ClinicalTrials
DiarrheaD003967HP:0002014diarrhea3ClinicalTrials
Irritable Bowel SyndromeD043183EFO:0000555irritable bowel syndrome3ClinicalTrials
HIV InfectionsD015658EFO:0000180HIV-1 infection2ClinicalTrials
HIV InfectionsD015658EFO:0000764HIV infection2ClinicalTrials
Helicobacter InfectionsD0164813ClinicalTrials
Hepatic EncephalopathyD0065013ClinicalTrials
Vaginosis, BacterialD016585EFO:0003932bacterial vaginosis2ClinicalTrials
Digestive System DiseasesD004066EFO:0000405digestive system disease3ClinicalTrials
Rectal NeoplasmsD012004EFO:1000657rectum cancer3ClinicalTrials
Cholangitis, SclerosingD015209EFO:0004268sclerosing cholangitis1ClinicalTrials
Liver CirrhosisD008103EFO:0001422cirrhosis of liver3ClinicalTrials
Liver DiseasesD008107EFO:0001421liver disease2ClinicalTrials
NeoplasmsD009369EFO:0000311cancer1ClinicalTrials
Heart Failure, SystolicD054143EFO:1001207systolic heart failure2ClinicalTrials
Hepatitis, AlcoholicD006519EFO:1001345Hepatitis, Alcoholic3ClinicalTrials
Parkinson DiseaseD010300EFO:0002508Parkinson's disease3ClinicalTrials
Persian Gulf SyndromeD018923EFO:0007430persian gulf syndrome1ClinicalTrials
Renal Insufficiency, ChronicD051436EFO:0003884chronic kidney disease0ClinicalTrials
RosaceaD012393EFO:1000760rosacea2ClinicalTrials

Clinical Data

ClinicalTrials.gov RIFAXIMIN
The Cochrane Collaboration RIFAXIMIN

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
785.9 785.3524 6.16 2 198.38 ACID


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
13 5 3 14 5 3


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
2.83 5.6 3.35 .32 4 57 0.11

Structural Alerts

There are 5 structural alerts for CHEMBL1617. To view alerts please click here.

Compound Cross References

ATC D - DERMATOLOGICALS
D06 - ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
D06A - ANTIBIOTICS FOR TOPICAL USE
D06AX - Other antibiotics for topical use
D06AX11 - rifaximin

A - ALIMENTARY TRACT AND METABOLISM
A07 - ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A07A - INTESTINAL ANTIINFECTIVES
A07AA - Antibiotics
A07AA11 - rifaximin

ChemSpider ChemSpider:NZCRJKRKKOLAOJ-XRCRFVBUSA-N
DailyMed rifaximin
PubChem SID: 144205082
Wikipedia Rifaximin

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL1617



ACToR 80621-81-4
BindingDB 50347620
ChEBI 75246
ChemicalBook CB5244184
DrugBank DB01220
DrugCentral 2379
eMolecules 32278142 29781310 30154455 31590059 26943529
EPA CompTox Dashboard DTXSID7045998
FDA SRS L36O5T016N
IBM Patent System 770F4C15379088BA6733595A71171A75
Mcule MCULE-7361349450
MolPort MolPort-046-416-955 MolPort-003-850-182
PDBe RXM
PharmGKB PA164752443
PubChem 6436173
PubChem: Drugs of the Future 12012727
PubChem: Thomson Pharma 14864871 14864870
Selleck Rifaximin(Xifaxan)
SureChEMBL SCHEMBL124066
ZINC ZINC000169621200

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/NZCRJKRKKOLAOJ-XRCRFVBUSA-N spacer
spacer